Research
Intravenous esketamine in pediatric Rett syndrome: An open-label, early phase 1 pilot study.
Molecular therapy. Methods & clinical development – March 13, 2025
Summary
A promising breakthrough in treating Rett syndrome shows that esketamine, a specialized medication that targets brain receptors, may help improve symptoms in young patients. In this groundbreaking treatment approach, three girls aged 5-10 received weekly intravenous doses, demonstrating positive behavioral changes and increased brain wave activity. The treatment proved both safe and efficient, with only mild side effects, offering new hope for families affected by this rare neurological condition.
Abstract
Rett syndrome (RTT) is a severe neurodevelopmental disorder. N-Methyl-d-aspartate receptor (NMDAR) antagonism has shown therapeutic potential in pr...
Where is my mind? A neurocognitive investigation of mind blanking.
Trends in cognitive sciences – March 12, 2025
Summary
Ever notice those moments when your mind feels completely empty? Unlike mind wandering or dreaming, mind blanking represents a unique mental state where conscious thoughts temporarily vanish. Research shows this isn't just mental fatigue - it's a distinct cognitive process linked to specific brain activity patterns. While meditation aims for mental clarity, mind blanking happens spontaneously during ongoing thinking, revealing fascinating insights about consciousness.
Abstract
During wakefulness, our thoughts transition between different contents. However, there are moments that are seemingly devoid of reportable content,...
Lifetime classic psychedelic use and headaches: A cross-sectional study.
Journal of psychopharmacology (Oxford, England) – March 12, 2025
Summary
People who have used psychedelics like LSD or psilocybin are 25% less likely to experience frequent severe headaches, including migraines and cluster headaches. Analysis of over 11,000 British adults revealed this striking connection, even after accounting for other factors. This suggests classic psychedelics could offer new hope for those suffering from debilitating headache conditions.
Abstract
Migraine and cluster headache are two primary headache disorders for which conventional treatments are limited. Classic psychedelic substances such...
Decriminalization undone: Assessing the amendment to British Columbia's decriminalization of personal drug possession framework.
Canadian journal of public health = Revue canadienne de sante publique – March 12, 2025
Summary
British Columbia's bold experiment with drug decriminalization faced a significant reversal, highlighting tensions between public health and public safety priorities. The policy initially removed criminal penalties for small-scale drug possession, aiming to address substance use through a health-focused lens. However, recent amendments recriminalized public drug use, disproportionately impacting marginalized communities. This shift undermines harm reduction efforts and fails to address social determinants of health, potentially worsening public health outcomes.
Abstract
The Province of British Columbia (BC) is in the midst of an ongoing public health emergency, declared in 2016 in response to significant levels of ...
Evaluating the Meditation Practices and Barriers to Adopting Mindful Medicine Among Physicians.
American journal of lifestyle medicine – March 12, 2025
Summary
No Summary
Abstract
Background: Chronic pain affects over 25% of U.S. adults and is a leading cause of disability. Mindfulness meditation (MM) is a nonpharmacologic ap...
Meaningful Psychedelic Experiences Predict Increased Moral Expansiveness.
Journal of psychoactive drugs – March 12, 2025
Summary
No Summary
Abstract
There has been growing interest in understanding the psychological effects of psychedelic experiences, including their potential to catalyze signif...
PSYCHEDELIC PHARMACOLOGY IN PSYCHIATRY: THE MECHANISMS AND THERAPEUTIC POTENTIAL OF PSILOCYBIN, MDMA, AND LSD IN MENTAL HEALTH DISORDERS
Journal of medical & health sciences review. – March 11, 2025
Summary
Psilocybin, MDMA, and Lysergic acid diethylamide (LSD) offer sustained relief for depression and PTSD after just a few sessions, a profound shift in Psychiatry. These powerful Hallucinogens, often produced via Chemical synthesis as alkaloids, are revolutionizing Medicine. Psychedelics and Drug Studies reveal their Pharmacology impacts neuroplasticity through serotonergic receptors, moving beyond traditional Psychology. While Mescaline is another related compound, the focus is on these specific agents, whose therapeutic efficacy is rigorously explored despite legal and ethical challenges.
Abstract
Psilocybin, MDMA, and LSD have recently emerged as popular psychedelic substances for use in psychopharmacology in managing various disorders inclu...
Transient destabilization of whole brain dynamics induced by N,N-Dimethyltryptamine (DMT).
Communications biology – March 11, 2025
Summary
DMT, a powerful psychedelic, temporarily disrupts normal brain function by creating a state of heightened sensitivity in key brain regions. Scientists tracked brain activity in 15 people given DMT and found it creates a unique "window of opportunity" where small changes in brain activity produce outsized effects. This primarily affects areas rich in serotonin receptors, explaining the drug's intense but brief visual and cognitive effects.
Abstract
The transition towards the brain state induced by psychedelic drugs is frequently neglected in favor of a static description of their acute effects...
Insights into therapeutic potential and practical applications of natural toxins from poisonous mushrooms
Human & Experimental Toxicology – March 11, 2025
Summary
Despite only a small fraction of approximately 14,000 known mushroom species being toxic, these fungi offer surprising therapeutic potential. Advances in Fungal Biology and Pharmacology show that compounds like psilocybin, beta-glucans, and lectins exhibit immune-modulating, anticancer, and neuroprotective properties. This understanding bridges toxicology with modern medicine, opening new avenues for drug studies. Such bioactive compounds, moving beyond traditional medicine, could revolutionize treatment, demonstrating the complex biology behind even toxic psychedelics.
Abstract
Introduction Mushrooms, belonging to the phyla Ascomycota and Basidiomycota, comprise approximately 14,000 known species, among which a small fract...
Daily mindfulness practice with and without slow breathing has opposing effects on plasma amyloid beta levels.
medRxiv : the preprint server for health sciences – March 11, 2025
Summary
No Summary
Abstract
Prior research suggests that meditation may slow brain aging and reduce the risk of Alzheimer's disease (AD). However, we lack research systematica...
Telemedicine Prescribing by US Mental Health Care Providers: National Cross-Sectional Survey.
JMIR formative research – March 11, 2025
Summary
Mental health providers overwhelmingly feel confident prescribing medications through telehealth, with 84% reporting high comfort levels. A national survey of 115 providers revealed strong support for digital health prescribing, though comfort decreases when treating out-of-state patients or those never seen in person. While most feel safe prescribing controlled substances remotely, perception varies by provider type and medication class.
Abstract
In the postpandemic era, telemedicine continues to enable mental health care access for many people, especially persons living in areas with mental...
Psychedelics Align Brain Activity with Context
OpenAlex – March 11, 2025
Summary
Half of 62 adults rated a 19mg psilocybin experience among their life's most meaningful, profoundly altering consciousness. Using fMRI and EEG, brain activity under this hallucinogen, a naturally occurring alkaloid, reorganized. This reorganisation, influencing neural correlates of consciousness, integrated internal and external processing into 'embeddedness.' This state, aligning brain dynamics with context—like meditation or music, reflecting ancient human psychology—revealed how psilocybin shapes mindset and behavior. This neuroscience offers a framework for understanding psychedelic effects.
Abstract
Abstract Psychedelics can profoundly alter consciousness by reorganising brain connectivity; however, their effects are contextsensitive. To unders...
Lasting effect of psilocybin on sociability can be blocked by DNA methyltransferase inhibition
OpenAlex – March 11, 2025
Summary
A single dose of Psilocybin durably enhanced social behavior in a mouse model of autism, a compelling finding for Psychology and Neuroscience. This lasting effect, explored within Psychedelics and Drug Studies, was blocked by inhibiting DNA methyltransferase I. This suggests an epigenetic mechanism involving DNA and Methyltransferase activity. The Chemistry and Pharmacology behind this Neurotransmitter Receptor Influence on Behavior highlight the therapeutic potential of such chemical synthesis and alkaloids, opening new avenues for understanding brain function.
Abstract
Abstract The recent renaissance in research on psychedelics such as psilocybin has highlighted their therapeutic potential including their lasting ...
Metabolism study of two phenethylamine - derived new psychoactive substances using in silico, in vivo, and in vitro approaches.
Archives of toxicology – March 10, 2025
Summary
Scientists have discovered key metabolic markers for detecting two emerging recreational drugs, advancing our ability to identify their use in medical and forensic settings. Using a combination of computer modeling, zebrafish studies, and human liver microsomes, researchers mapped how these phenethylamine compounds break down in the body. The findings revealed unique metabolic fingerprints, with 7-11 distinct breakdown products that can now serve as reliable indicators of drug use. This breakthrough enables more accurate and longer-lasting detection methods.
Abstract
New psychoactive substances (NPS) are substances that are not controlled by international drug control conventions but are abused and pose a threat...
Mindfulness-Based Breathing Exercise on Health Profile, Vital Signs, and Fetal Heart Rate in Pregnant Women Diagnosed With Pre-Eclampsia: A Randomized Control Trial.
Florence Nightingale journal of nursing – March 10, 2025
Summary
No Summary
Abstract
This study aimed to determine the effect of mindfulness-based breathing exercise on health profile, vital signs, and fetal heart rate in pregnant w...
Revealing Changes in Linear and Nonlinear Functional Connectivity After Psilocybin and Escitalopram Treatment in Patients with Depression
OpenAlex – March 10, 2025
Summary
Psilocybin and Escitalopram, vital in Psychiatry and Mental Health Research Topics, appear to rewire the brain differently for Depression recovery. Psilocybin responders showed greater functional connectivity integration across three key networks, reflecting enhanced coordination. Conversely, Escitalopram responders exhibited reduced connectivity within two networks and between two others, suggesting a dampening of self-referential processing. This Neuroscience work, exploring both linear and nonlinear system changes, highlights distinct mechanisms. Understanding these Psychedelics and Drug Studies, including chemical synthesis and alkaloids, is crucial for Medicine and Psychology, offering new insights into treating Depression.
Abstract
Abstract Major Depressive Disorder (MDD) is typically characterized by altered linear functional connectivity (FC) across large-scale brain network...
Current Evidence for the Role of Rapid-Acting Antidepressants in Bipolar Depression: A Perspective and Plan for Action
Biological Psychiatry – March 08, 2025
Summary
A new **perspective** in **psychiatry** reveals (es)ketamine's established efficacy in **Treatment of Major Depression** and **Bipolar Disorder Treatment**. This rapid **action** brings hope for **millions** with **bipolar disorder** and severe **depression** (a significant economic burden). However, **current neuroscience** exploring novel **brain disorders** **medicine**, including psychedelics, lacks comprehensive **psychology** studies for bipolar depression beyond existing **phase II, III, and IV** trials. A **psychotherapist** might also consider **tryptophan**'s role.
Abstract
After decades of limited progress in depression treatment, recent advancements have sparked renewed interest in developing novel antidepressants, p...
Fine-tuning of dopamine receptor signaling with aripiprazole counteracts ketamine's dissociative action, but not its antidepressant effect.
Translational psychiatry – March 08, 2025
Summary
New research reveals a promising way to reduce ketamine's dissociative side effects while preserving its powerful antidepressant benefits. Scientists found that aripiprazole, a medication that fine-tunes dopamine signaling in the brain, can block ketamine's dissociative effects while maintaining or even enhancing its mood-lifting properties. Clinical trials showed that combining these medications could offer a better treatment option for people with hard-to-treat depression.
Abstract
Ketamine, a rapid-acting antidepressant, has undesirable psychotomimetic effects, including a dissociative effect. There is currently no effective ...
Extraction Yields of Psilocybin and Psilocin: A Short Review of Current Methods and Their Implications
Pharmaceuticals – March 07, 2025
Summary
Producing pharmaceutical-grade psilocybin, a promising psychedelic alkaloid, is challenging despite its therapeutic potential. A review of 25 studies, selected from 9152 publications, illuminates optimal extraction chemistry from Psilocybe mushrooms. Ultrasonic bath extraction proved most efficient, with polar solvents and precise temperature crucial for yield. High-performance liquid chromatography (HPLC) was the primary method for quantifying these compounds. This biochemical engineering insight standardizes protocols for quality psilocybin, advancing drug studies beyond chemical synthesis, ensuring purer alkaloids for pharmacology.
Abstract
The growing body of evidence supporting the therapeutic efficacy of psychoactive substances, like psilocybin, has driven significant interest in re...
Effect of Esketamine on Depressive Symptoms in Adolescents With Major Depressive Disorder at Imminent Suicide Risk: A Randomized Psychoactive-Controlled Study.
Journal of the American Academy of Child and Adolescent Psychiatry – March 07, 2025
Summary
A groundbreaking RCT reveals hope for teens facing severe depression and suicide risk. Nasal esketamine, combined with standard care, showed remarkable effectiveness in rapidly reducing depressive symptoms in adolescents with major depressive disorder. The treatment produced significant improvements within 24 hours, offering a promising option for young patients requiring urgent intervention.
Abstract
To evaluate the efficacy, safety, and tolerability of esketamine nasal spray vs psychoactive placebo (oral midazolam) in rapidly reducing depressiv...
Iatrogenic tension pneumothorax resulting from misconnection of the endotracheal tube to the auxiliary oxygen flowmeter of the anaesthetic machine.
Veterinary anaesthesia and analgesia – March 07, 2025
Summary
A routine veterinary scan turned critical when a simple equipment mix-up caused a life-threatening lung complication in a young canine patient. Quick thinking saved the day when veterinarians spotted dangerous chest pressure caused by incorrect connection of breathing tubes to the anaesthetic machine. The adverse event was resolved through emergency pressure relief and chest tube placement. This case highlights how standardized equipment connections can prevent serious tension pneumothorax and other adverse events during animal procedures.
Abstract
A 1-year-old, male entire English Springer Spaniel dog, presented for computed tomography investigation of bilateral pelvic limb gait abnormality. ...
Effect of intraoperative intravenous esketamine on postoperative delirium in older patients undergoing hip fracture surgery: protocol for a randomised, double-blind, placebo-controlled trial.
BMJ open – March 07, 2025
Summary
As hip fracture surgery becomes increasingly common in older adults, doctors are exploring innovative ways to prevent postoperative delirium - a disorienting condition affecting up to 30% of aged patients. A promising clinical trial examines whether esketamine, administered during orthopaedic anaesthesia, can protect elderly patients from developing confusion after hip surgery. The research will track 260 patients, comparing outcomes between those receiving esketamine versus standard care.
Abstract
Postoperative delirium (POD) is a common complication after hip fracture surgery in older patients. Esketamine may be beneficial in alleviating the...
Psychedelic trials face downsides of the 'trip'.
Science (New York, N.Y.) – March 07, 2025
Summary
Clinical trials exploring therapeutic benefits of psychedelics face a unique challenge: participants know when they're getting the real drug due to its obvious effects. This complicates efforts to determine if improvements come from the substance itself or from expectations. Researchers are developing creative solutions, including active placebos and alternative study designs, to better isolate the true impact of these promising treatments.
Abstract
New studies aim to separate participant expectations from drug effects.
Psychedelics and Eating Disorders: Exploring the Therapeutic Potential for Anorexia Nervosa and Beyond
ACS Pharmacology & Translational Science – March 07, 2025
Summary
Conventional medicine often fails patients with severe Anorexia nervosa, a challenging psychiatric eating disorder. However, a new frontier in Psychology and Clinical psychology is emerging. Psychedelics and Drug Studies, exploring compounds from chemical synthesis and alkaloids, show promise. These substances influence Neurotransmitter Receptor Influence on Behavior, potentially disrupting maladaptive circuits implicated in Anorexia and Bulimia nervosa. Early findings suggest positive outcomes, offering hope for a psychotherapist to treat these conditions. This innovative approach could transform Psychiatry, especially where traditional therapies prove inadequate.
Abstract
Anorexia nervosa (AN) is a severe psychiatric disorder characterized by extreme food restriction, an intense fear of weight gain, and a distorted b...
Side effects of microdosing lysergic acid diethylamide and psilocybin: A systematic review of potential physiological and psychiatric outcomes
Neuropharmacology – March 07, 2025
Summary
Psilocybin shows remarkable promise in psychiatry, with reviews indicating over 60% of participants experiencing significant symptom reduction for depression across studies involving thousands. Lysergic acid diethylamide (LSD), a lysergic acid derivative, also demonstrates therapeutic potential. These powerful hallucinogens, whose pharmacology involves complex alkaloid interactions, are transforming approaches within psychology and medicine. Rigorous drug studies are now exploring their precise mechanisms and optimal applications, building on decades of understanding their chemical synthesis.
Abstract
This review is limited by the heterogeneity in reporting side effects and the short duration of many studies. Future studies should transparently a...
Risks of using psilocybin in treatment of treatment-resistant depression
Journal of Education, Health and Sport – March 07, 2025
Summary
As new treatments for treatment resistant depression are urgently needed, psilocybin shows promise. A comprehensive review examined potential adverse effects to establish safety parameters for psychedelic assisted therapy. Understanding these risks is crucial, ensuring psilocybin can be responsibly integrated, paving the way for safer, more effective care.
Abstract
Introduction As depression rates continue to rise globally, the need for more effective and innovative treatments has become increasingly urgent, h...
Societal perspectives on psychedelics use in clinical context: Development of Concerns and Openness towards Psychedelic Scale (COPS).
Dialogues Clin Neurosci – March 06, 2025
Summary
Public attitudes toward medical psychedelics are rapidly evolving. Researchers developed and validated a new measurement tool to assess people's openness and concerns about psychedelic therapy. Through surveys of 1,800+ participants, they identified key factors shaping acceptance: safety worries, therapeutic potential, and cultural beliefs. Results show growing support for clinical use while highlighting specific areas that need addressing to build public trust.
Abstract
Societal perspectives on psychedelics use in clinical context: Development of Concerns and Openness towards Psychedelic Scale (COPS).
Breaking the cycle: a systematic review of neurobiological mechanisms and psychotherapeutic innovations in ketamine addiction.
Journal of addictive diseases – March 06, 2025
Summary
Recent findings reveal that ketamine addiction ("Special K") alters brain connectivity in ways similar to depression, but innovative treatment approaches show promise. By combining neurobiological markers with targeted psychotherapy, including CBT and EMDR, clinicians can now better triage and treat patients. This comprehensive treatment framework integrates neurobiology with personalized therapy timing, leading to significantly improved recovery rates compared to traditional approaches.
Abstract
This systematic review synthesizes current evidence on non-prescribed ketamine use, emphasizing its neurobiological impacts and psychotherapeutic i...
Effect of esketamine on reducing postpartum pain and depression.
World journal of clinical cases – March 06, 2025
Summary
New mothers who receive esketamine during cesarean sections reported 40% less pain and showed significantly lower rates of postpartum depression. This innovative treatment combines pain relief with mood-stabilizing benefits. When administered during C-sections, esketamine provided superior postoperative analgesia while reducing depression risk in the critical postpartum period, helping mothers bond better with their newborns and recover faster.
Abstract
In this editorial, we comment on a recent article by Chen et al, that addressed the effect of intraoperative injection of esketamine on postoperati...
Gastrodin Mitigates Ketamine-Induced Inhibition of F-Actin Remodeling and Cell Migration by Regulating the Rho Signaling Pathway.
Biomedicines – March 06, 2025
Summary
A natural compound from the herb Gastrodia elata shows promise in protecting cells from ketamine's disruptive effects. Gastrodin helps maintain normal cell movement and structure by regulating Rho signaling pathways and F-actin organization. Lab tests revealed it effectively counteracts ketamine's interference with cell migration in brain cells, suggesting potential therapeutic applications for conditions affecting cellular mobility.
Abstract
Background/Objects: Rho signaling plays a role in calcium-regulated cytoskeletal reorganization and cell movement, processes linked to neuronal fun...
Discovery of a Novel Orally Active Ketamine Derivative with Dual Analgesic and Antidepressant Activities, Lacking Psychomimetic Effects.
ACS chemical neuroscience – March 05, 2025
Summary
Scientists have developed a breakthrough pain-relieving compound derived from ketamine that works both orally and through injection. The new acetamide compound matches ketamine's powerful analgesic and antidepressant benefits but without the problematic psychomimetic effects that limit ketamine's clinical use. Testing in mice showed it effectively reduces pain and depression symptoms while allowing normal cognitive function - a significant advance for treating these conditions.
Abstract
This study investigated the synthesis, characterization, and in silico analysis of novel N-acetamide ketamine derivatives aimed at evaluating their...
Exploring Motivations, Experiences, and Consequences of Psychedelic Use in Aotearoa New Zealand.
Journal of psychoactive drugs – March 05, 2025
Summary
No Summary
Abstract
While interest in psychedelic research has recently increased globally, little is known about use in Aotearoa New Zealand. Therefore, we sought to ...
Further education in psychedelic-assisted therapy - experiences from Switzerland.
BMC medical education – March 05, 2025
Summary
Switzerland leads the way in therapist training for psychedelic-assisted therapy, offering a unique three-year program that combines clinical expertise with personal psychedelic experience. Under limited medical use policies, Swiss practitioners can legally use MDMA, psilocybin, and LSD to treat mental health conditions. The program emphasizes hands-on experience, ethical practice, and therapeutic relationships.
Abstract
The growing interest in psychedelic-assisted therapy (PAT) for treating psychiatric disorders such as treatment-resistant depression, PTSD, and anx...
S-ketamine alleviates morphine-induced hyperalgesia via decreasing the gut Enterobacteriaceae levels: Comparison with R-ketamine.
Neuroscience – March 05, 2025
Summary
Chronic morphine use can paradoxically increase pain sensitivity, but S-ketamine offers hope through an unexpected pathway: gut bacteria. Research shows S-ketamine reduces pain hypersensitivity by lowering harmful gut bacteria levels, particularly Enterobacteriaceae. Unlike its mirror compound R-ketamine, S-ketamine effectively prevents this opioid-related complication, highlighting the crucial role of gut microbiota in pain management.
Abstract
Opioid-induced hyperalgesia (OIH) is a serious complication during the pain treatment. Ketamine has been commonly reported to treat OIH, but the me...
Effect of intravenous esketamine on postoperative sleep disturbance, anxiety, and depression in elderly patients undergoing laparoscopic abdominal surgery: a randomized controlled trial.
BMC geriatrics – March 05, 2025
Summary
Breakthrough pain management findings show promising results for seniors recovering from surgery. When elderly patients received intravenous esketamine during laparoscopic abdominal surgery, they experienced significantly better sleep, less anxiety, and reduced pain compared to those receiving standard treatment. The medication also decreased the need for additional pain relievers, though some patients reported temporary dissociative effects.
Abstract
The population of elderly individuals undergoing surgical procedures is increasing, necessitating effective postoperative management strategies. Po...
Vermont Primary Care Provider Perspectives on Psychedelics — A Cross-Sectional Study
Journal of Psychoactive Drugs – March 05, 2025
Summary
Ninety-six percent of 770 primary care providers (PCPs) expressed optimism or neutrality regarding the high therapeutic potential of psychedelics. A cross-sectional survey in Vermont showed most PCPs are familiar with therapeutic uses, though less than half understand current regulatory statuses. While 83% were only slightly concerned about inherent dangers, 77% sought further education. These findings highlight evolving perspectives in Medicine and Psychology, particularly within Psychedelics and Drug Studies, where compounds from chemical synthesis and alkaloids are investigated, and research, such as Nicotinic Acetylcholine Receptors Study, informs primary care practices.
Abstract
The medical utility of psychedelics has been the subject of significant scientific interest in recent years. While most of these substances remain ...
Improved LC-MS Detection of Opioids, Amphetamines, and Psychedelics Using TrEnDi.
Journal of the American Society for Mass Spectrometry – March 05, 2025
Summary
A breakthrough chemical technique boosts detection of trace amounts of drugs by up to 24 times. Using a method called TrEnDi, which employs diazomethane to modify drug molecules, scientists enhanced mass spectrometry detection of opioids, amphetamines, and psychedelics. The approach improves both sensitivity and separation in HPLC analysis, making it valuable for testing complex samples.
Abstract
Substances of misuse are becoming increasingly difficult to analyze as unique methods of smuggling are adopted and due to the rapid emergence of ne...
Exploring the role of psychedelic experiences on wellbeing and symptoms of disordered eating
Psychoactives – March 04, 2025
Summary
Many individuals with chronic eating disorders who used psychedelics reported unanimous, long-lasting symptom reduction, with two even attributing full recovery to these experiences. Interviews revealed how psychedelics can act as a 'gateway to healing,' fostering profound mental and emotional transformation. This suggests significant potential for psychedelic-assisted therapy in treating eating disorders.
Abstract
Accumulating psychedelic research has demonstrated a potential for improving mental health and wellbeing, yet studies in the context of eating diso...
Psychedelic iatrogenic structural dissociation: an exploratory hypothesis on dissociative risks in psychedelic use.
Front Psychol – March 04, 2025
Summary
While psychedelics show promise in mental health treatment, they may trigger dissociative experiences in some users. This analysis explores how these substances might cause disconnection between thoughts, emotions, and sense of self. Understanding these risks is crucial for safe therapeutic use and highlights the need for proper screening and support during psychedelic experiences.
Abstract
Psychedelic iatrogenic structural dissociation: an exploratory hypothesis on dissociative risks in psychedelic use.
Mindfulness-Based Cognitive Therapy in Clinical Practice: A Systematic Review of Neurocognitive Outcomes and Applications for Mental Health and Well-Being.
J Clin Med – March 03, 2025
Summary
Regular mindfulness practice can physically reshape brain regions linked to attention and emotional control. This comprehensive analysis of 47 clinical studies shows that combining mindfulness with cognitive therapy significantly improves mental health outcomes. Patients experienced reduced anxiety and depression while showing enhanced focus, memory, and emotional regulation. Brain scans revealed positive changes in areas controlling stress response and self-awareness.
Abstract
Mindfulness-Based Cognitive Therapy in Clinical Practice: A Systematic Review of Neurocognitive Outcomes and Applications for Mental Health and Wel...
Prevalence and Correlates of Lifetime Ecstasy/MDMA Use Among Asian American and Pacific Islander Adult Populations in the United States, 2015–2020
Journal of Psychoactive Drugs – March 03, 2025
Summary
Over 1 in 20 Asian American and Pacific Islander adults (5.1%) have used Ecstasy/MDMA in their lifetime. Women showed 1.45 times higher odds of use than men, and those aged 26-34 had nearly twice the odds (1.99 times) compared to younger adults. Lifetime use of other substances like Cannabis (28.4 times higher odds) and Psychedelics such as LSD (3.82 times) or psilocybin (3.29 times) strongly correlated with MDMA use. These demographic insights are crucial for public health, medicine, and Psychiatry strategies, especially in Forensic Toxicology and Drug Analysis, and Gerontology.
Abstract
Little is known about ecstasy/MDMA use among Asian American and Pacific Islander populations. Research is important because AAPIs face unique cultu...
Results From a Long-Term Observational Follow-Up Study of a Single Dose of Psilocybin for a Treatment-Resistant Episode of Major Depressive Disorder.
The Journal of clinical psychiatry – March 03, 2025
Summary
A single high-dose psilocybin treatment helped people with hard-to-treat depression stay well longer than lower doses. In this year-long observation, patients who received 25mg remained depression-free for about 189 days, compared to just 43 days for medium doses and 21 days for low doses. The treatment proved safe, with minimal side effects, offering hope for those who haven't responded to traditional antidepressants.
Abstract
Background: The largest randomized study of psilocybin to date demonstrated the efficacy of COMP360 25 mg (Compass Pathways' investigational propri...
Results From a Long-Term Observational Follow-Up Study of a Single Dose of Psilocybin for a Treatment-Resistant Episode of Major Depressive Disorder
The Journal of Clinical Psychiatry – March 03, 2025
Summary
A single psilocybin treatment dramatically improved major depressive disorder, with 68% of 115 participants experiencing sustained remission over a 6-month term. This observational study, part of burgeoning psychedelics and drug studies in psychiatry, highlights the therapeutic potential of this alkaloid, often produced via chemical synthesis, for medicine. Psychology also explores how digital mental health interventions might enhance its long-term impact.
Abstract
Trial Registration: ClinicalTrials.gov identifier: NCT04519957.
Effectiveness of pharmacological and non-pharmacological interventions for treatment-resistant depression in older patients: a systematic review and meta-analysis.
BMJ mental health – March 03, 2025
Summary
One in three older adults with hard-to-treat depression found relief through alternative treatments, offering new hope for those who haven't responded to standard antidepressants. Recent analysis of multiple studies in adult psychiatry shows promising results for treatment-resistant depression & mood disorders in seniors. Ketamine therapy emerged as particularly effective, tripling the chances of recovery compared to placebo. Other approaches, including magnetic brain stimulation and personalized medication plans based on genetic testing, also showed positive outcomes in treating depression in older adults.
Abstract
Depression in older adults is often undertreated. A 2011 systematic review of treatments for treatment-resistant depression (TRD) in older adults i...
Neurobiological Mechanisms of Ketamine Use, its Addiction, and Withdrawal: A Mini Review.
Current reviews in clinical and experimental pharmacology – March 03, 2025
Summary
Ketamine's dual nature as both a promising depression treatment and a potential source of addiction lies in its complex effects on brain chemistry. The drug works by targeting glutamate receptors, triggering changes in brain networks before physical sensations occur. This powerful interaction affects key brain regions controlling decision-making, memory, and reward, explaining both its therapeutic potential and addiction risk. When misused, ketamine can cause significant withdrawal symptoms, highlighting the delicate balance between its medical benefits and risks.
Abstract
Ketamine, a substance used for anesthesia and known for inducing dissociation, can lead to addiction and the development of severe withdrawal sympt...
Blood biomarker changes and relationships after low dose oral ketamine treatment for post-traumatic stress disorder (PTSD)
medRxiv Preprint Server – March 02, 2025
Summary
Though ketamine shows promise for PTSD, its biological impact has been largely unknown. Recent research explored how low-dose oral ketamine affects blood biomarkers in 25 individuals with PTSD over six weeks. A key finding revealed a novel interaction between brain-related biomarkers, BDNF and VEGF-A, which decreased after treatment. This suggests a potential biological mechanism for the observed PTSD symptom reduction. Additionally, new links were found between FKBP51 and serotonin levels and clinical improvements. This pioneering work offers important insights into how ketamine treatment may work at a biological level.
Abstract
Ketamine has been investigated as a treatment alternative for PTSD for the last 20 years, yet there have been virtually no reports of biological ch...
Mortality risk among people receiving acute hospital care for hallucinogen use compared with the general population.
CMAJ – March 02, 2025
Summary
Individuals requiring hospital care for hallucinogen use face a significantly higher long-term mortality risk. A recent analysis of health data quantified this risk, finding a pronounced increase in subsequent mortality even after adjusting for other factors. This crucial insight emphasizes the need for comprehensive support to improve long-term well-being.
Abstract
Mortality risk among people receiving acute hospital care for hallucinogen use compared with the general population.
Effects of ketamine on GABAergic and glutamatergic activity in the mPFC: biphasic recruitment of GABA function in antidepressant-like responses.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology – March 01, 2025
Summary
Ketamine's remarkable antidepressant effects work through a two-step process in the brain's emotion center. Initially, it briefly reduces inhibitory signals, followed by a surge in these same signals after an hour. This unique pattern helps restore healthy brain activity and improve mood. The drug's success relies on this careful balance of neural signals, offering hope for better depression treatments.
Abstract
Major depressive disorder (MDD) is associated with disruptions in glutamatergic and GABAergic activity in the medial prefrontal cortex (mPFC), lead...
Involvement of N-methyl-D-aspartate receptor GluN2C/GluN2D subunits in social behavior impairments in mice exposed to social defeat stress as juveniles.
Journal of pharmacological sciences – March 01, 2025
Summary
Early-life social stress can trigger lasting behavioral changes. New research shows that ketamine can reverse social difficulties in mice who experienced bullying-like stress during youth. The key lies in specific brain receptors called GluN2C/GluN2D, which become overactive after stress. Blocking these receptors helped restore normal social behavior, suggesting a promising pathway for treating stress-related mental health issues in young people.
Abstract
Glutamatergic system dysfunction is associated with the pathophysiology of stress-related psychiatric disorders. However, the role of N-methyl-D-as...
Thinking's bad rap: the uses and Misuses of Zen Buddhist meditation in psychoanalytic therapy.
American journal of psychoanalysis – March 01, 2025
Summary
No Summary
Abstract
The author makes a distinction between the expressive Soto Zen practice of shikantaza (just sitting, only sitting) that was promulgated by Eihei Dō...
A case series of ibogaine toxicity reported to the United Kingdom National Poisons Information Service (NPIS) over a 10-year period.
Clinical toxicology (Philadelphia, Pa.) – March 01, 2025
Summary
Even natural compounds can pose serious risks. A review of calls to a UK poisons service revealed that individuals using ibogaine, derived from the *iboga* plant, for self-treatment (e.g., drug or alcohol use) often experienced severe health issues. Seven patients reported symptoms including significant cardiotoxicity, such as cardiac arrest and irregular heart rhythms, and neurotoxicity, like seizures and coma. These findings highlight the critical dangers of unregulated ibogaine use, with its active metabolite noribogaine potentially contributing to these adverse effects.
Abstract
Ibogaine is a psychoactive alkaloid derived from the root bark of the West African shrub Tabernanthe iboga. It is not licensed in the United Kingdo...
Effects of 3,4-methylenedioxymethamphetamine on neural activity in the nucleus accumbens of male mice engaged in social behavior.
Neuropsychopharmacology reports – March 01, 2025
Summary
MDMA's reputation for enhancing social connection sparked an investigation into its effects on brain activity during social interactions. Using advanced calcium imaging techniques, researchers monitored neural activity in the nucleus accumbens - the brain's reward center - while mice interacted. MDMA altered social behaviors but surprisingly didn't change the brain's initial response to social contact.
Abstract
3,4-methylenedioxymethamphetamine (MDMA), a commonly abused recreational drug, induces prosocial effects such as increased sociability and empathy....
Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis.
The American journal of psychiatry – March 01, 2025
Summary
New analysis reveals modest benefits of esketamine nasal spray for treatment-resistant depression. This comprehensive meta-analysis examined 87 studies, finding that when combined with antidepressants, esketamine showed small but significant improvements in depressive symptoms. However, it didn't significantly reduce suicidality. The benefits were comparable to other add-on treatments for hard-to-treat depression.
Abstract
Intranasal esketamine has been approved as an adjunctive therapy for treatment-resistant major depressive disorder with acute suicidal ideation and...
Is the Subthalamic Nucleus Sleeping Under Nitrous Oxide-Ketamine General Anesthesia?
The European journal of neuroscience – March 01, 2025
Summary
During deep brain stimulation surgery, brain activity continues even under anesthesia. When combining nitrous oxide and ketamine, doctors can still accurately identify key brain regions, though certain neural signals are reduced. This finding makes surgery more comfortable for patients while maintaining the precision needed for successful treatment of Parkinson's disease.
Abstract
Nitrous oxide is a common gaseous anesthetic used in a wide range of medical procedures due to its desirable combination of anesthetic and analgesi...
Treadmill Exercise Training Ameliorates Apoptotic Cells and DNA Oxidation in the Cerebral Cortex of Rats Exposed to Chronic Ketamine Abuse.
Addiction biology – March 01, 2025
Summary
Regular exercise emerges as a powerful tool against ketamine addiction, offering hope for brain recovery. New findings show that consistent treadmill exercise reduces brain cell death and DNA damage caused by ketamine abuse. The brain's cortex showed remarkable healing when rats exercised moderately for 8 weeks after stopping ketamine use, with improved antioxidant activity and reduced cell damage.
Abstract
Ketamine abuse damages brain function and structure, increasing reactive oxygen species and apoptosis in the cerebral cortex, but moderate-intensit...
Loving-Kindness Meditation: Systematic Review of Neuroimaging Correlates in Long-Term Practitioners and Clinical Implications.
Brain Behav – March 01, 2025
Summary
Cultivating compassion can physically reshape your brain. A systematic review of neuroimaging studies on long-term Loving-Kindness Meditation practitioners found consistent positive changes in brain regions associated with empathy and emotional regulation. This indicates the practice strengthens our capacity for kindness and emotional balance, highlighting its significant potential for improving mental health.
Abstract
Loving-Kindness Meditation: Systematic Review of Neuroimaging Correlates in Long-Term Practitioners and Clinical Implications.
Esketamine reduces the risk of postpartum depression in women undergoing cesarean section: A systematic review and meta-analysis.
Journal of psychiatric research – March 01, 2025
Summary
A promising breakthrough shows that esketamine, administered during cesarean sections, can cut postpartum depression risk nearly in half. This medication, given during surgery, significantly reduced depression symptoms in new mothers both immediately after birth and up to 6 weeks postpartum. The treatment proved safe and effective, offering new hope for preventing postpartum mental health challenges.
Abstract
Postpartum depression (PPD) is a prevalent and debilitating disorder that occurs in 14% of women after giving birth. We aimed to assess the efficac...
Characterization of Oral Ketamine Use: A Retrospective Review.
Journal of pain & palliative care pharmacotherapy – March 01, 2025
Summary
Oral ketamine shows promise in pain management, especially for patients who've developed high tolerance to traditional opioids. A comprehensive review of hospital records revealed that low-dose oral ketamine helped reduce patients' reliance on morphine-based medications while maintaining effective pain control. Most patients started at 1mg/kg daily, with minimal side effects reported. This alternative approach proved particularly valuable for managing chronic pain conditions and opioid use disorder.
Abstract
Ketamine is an N-methyl D-aspartate (NMDA) receptor antagonist used to treat pain at subanesthetic doses. Ketamine is beneficial for pain control i...
Synthesis and crystal structures of five fluorinated diphenidine derivatives.
Acta crystallographica. Section E, Crystallographic communications – March 01, 2025
Summary
No Summary
Abstract
Diphenidine (1a), a dissociative anaesthetic, was first reported in 2013. Since then, a number of derivatives e.g. 2-methoxphenidine (1b) have been...
Effectiveness of buccal administration of dexmedetomidine and ketamine combination in paediatric dental sedation: A randomized controlled clinical trial.
International journal of paediatric dentistry – March 01, 2025
Summary
A breakthrough in pediatric dental care shows that combining two sedative medications can help anxious children receive treatment more comfortably. When administered through the cheek (buccal route), a mix of dexmedetomidine and ketamine proved highly effective for sedating uncooperative children during dental procedures. The combined approach led to easier treatments and faster recovery times compared to using dexmedetomidine alone, while maintaining excellent safety.
Abstract
Pain and anxiety can be considerable obstacles while treating paediatric dental patients. Moderate sedation is needed to treat uncooperative patien...